{
  "Cancer Histology Subtype (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        974, 
        988
      ]
    }
  ], 
  "Cancer Histology Type (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        989, 
        998
      ]
    }
  ], 
  "Clinical History Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        806, 
        829
      ]
    }
  ], 
  "Comments Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2854, 
        2874
      ]
    }
  ], 
  "Final Diagnosis Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        889, 
        916
      ]
    }
  ], 
  "Laterality (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        918, 
        923
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2834, 
        2839
      ]
    }
  ], 
  "Macroscopic/Gross Description Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        579, 
        608
      ]
    }
  ], 
  "Microscopic Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2710, 
        2745
      ]
    }
  ], 
  "Nature of Specimen Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2787, 
        2813
      ]
    }
  ], 
  "Neoplasm Behaviour (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        965, 
        973
      ]
    }
  ], 
  "Neoplasm Grade Value (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1000, 
        1007
      ]
    }
  ], 
  "Neoplasm Grade-Score Name (At)": [
    {
      "__agreement__": "FALSE NEGATIVE", 
      "__annotator__": "Gemma", 
      "__extent": [
        1009, 
        1019
      ]
    }
  ], 
  "Organ/Body Structure (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        924, 
        930
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2840, 
        2846
      ]
    }
  ], 
  "Synoptic Report Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": ",Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1028, 
        1045
      ]
    }
  ], 
  "__text": "MSH|^~\\&|PathSys|Tennova Healthcare - Cleveland Laboratory^44D0309307^CLIA|eMARCPlus|TN Cancer Registry|20170917000049||ORU^R01^ORU_R01|201709170000490001|P|2.5.1|TN||||||||VOL_V_40_ORU_R01-CCR1^NAACCR_CP\nOBR|1||17-SC-001727^PathSys^44D0309307^CLIA|11529-5^SURGICAL PATH REPORT^LN|||20170831000000|||||||20170901000000|&Breast, Stereotactic biopsy, PQRS Breast IHC HER2|1285671198^^^^^^MD^^CMS^D^^^NPI||||||20170907000000|||F||||||C50.911^Malignant neoplasm of unspecified site of right female breast^I10~Z17.0^Estrogen receptor positive status [ER+]^I10|54321&&&&&&&&CMS\n\n\n\n\n\n\n\nPath report.gross description\n\nSubmitted in formalin labeled \", core biopsy, right breast mass\" are multiple white-brown fragments of tissue and blood clot, 2.4 x 2.7 x 0.2 cm in aggregate . Entirely submitted in 1 cassette.\n\n\nPath report.relevant Hx\n\nHistory - Palpable mass right breast 11:00,2.5 x 3.5 cm\n\n\nPath report.final diagnosis\n\nRight breast mass, stereotactic core biopsy:   Invasive micropapillary carcinoma, grade 1 (Nottingham method) CANCER CHECKLIST: BREAST: Biomarker Reporting Template 1.001.001.1000043 TEST(S) PERFORMED  Test(s) Performed: Estrogen Receptor (ER) Status, Progesterone Receptor (PgR) Status, HER2 by Immunohistochemistry (IHC), +Ki-67, p53.  ER Results: Positive  Percentage of Cells with Nuclear Positivity#: 91-100%  Average Intensity of Staining: Strong  Test Type (required for U.S.-based laboratories): Food and Drug Administration (FDA) cleared (specify test / vendor)  Food and Drug Administration (FDA) cleared (specify test / vendor): Ventana  Primary Antibody: SP1  PgR Results: Positive  Percentage of Cells with Nuclear Positivity#: 61-70%  Average Intensity of Staining: Moderate  Test Type (required for U.S.-based laboratories): Food and Drug Administration (FDA) cleared (specify test / vendor)  Food and Drug Administration (FDA) cleared (specify test / vendor): Ventana  Primary Antibody: 1E2  HER2 IHC Results: Negative (Score 1+)  Percentage of Cells with Uniform Intense Complete Membrane Staining: 0%  Test Type (required for U.S.-based laboratories): Food and Drug Administration (FDA) cleared (specify test / vendor): Ventana  Primary Antibody: 4B5  Ki-67 Results:  Percentage of Positive Nuclei: 10-20%  Primary Antibody: 30-9  Test type: Ventana  p53 Results: Negative  Percentage of Positive Nuclei: <5%, strong nuclear staining.  Primary Antibody: Bp53-11  Test type: Ventana METHODS  Cold Ischemia and Fixation Times: Meet requirements specified in latest version of the ASCO / CAP Guidelines  Cold Ischemia Time (min): 1-2min  Time of Fixation (hours): 11hours  Testing Performed on Block Number(s) (specify): 1A  Fixative: Formalin  Image Analysis: Not performed\n\n\nPath report.microscopic examination\n\nMicroscopic examination is performed.\n\n\nPath report.site of origin\n\nCore needle biopsy right breast mass\n\n\nPath report.comments\n\nComments - The grade is based on a score of 4 of 9 (glandular/acinar/tubular differentiation - 1, nuclear pleomorphism - 2, mitotic rate -1). See below for breast prognostic markers panel results. Prospective QA review done by Dr. J R Slemmer.\n\n\n"
}